This Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), provides $399,970 to Duo Oncology Inc. to develop DUO-207, an ultrasmall nanoparticle drug formulation for the treatment of pancreatic cancer. The project aims to improve upon existing nanomedicine treatments by developing a combination therapy that can more effectively penetrate the dense stromal tissue surrounding pancreatic tumors. Key innovations of DUO-207 include a polymer-conjugated gemcitabine that provides controlled drug release, and the ability to incorporate high doses of paclitaxel in a single 14nm nanoparticle. The funding will support preclinical studies to establish the safety and efficacy profile of DUO-207 compared to current standard of care therapies. The award period runs from August 15, 2024 to July 31, 2025.